SB-265610 | CAS#211096-49-0 | CXCR2 antagonist

MedKoo Cat#: 526278 | Name: SB-265610

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB-265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). It inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.

Chemical Structure

SB-265610

CAS#211096-49-0

Theoretical Analysis

MedKoo Cat#: 526278

Name: SB-265610

CAS#: 211096-49-0

Chemical Formula: C14H9BrN6O

Exact Mass: 356.0021

Molecular Weight: 357.17

Elemental Analysis: C, 47.08; H, 2.54; Br, 22.37; N, 23.53; O, 4.48

Price and Availability

Size	Price	Availability
10mg	USD 250.00	2 Weeks
25mg	USD 450.00	2 Weeks
50mg	USD 750.00	2 Weeks
100mg	USD 1,350.00	2 Weeks
200mg	USD 2,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SB-265610; SB 265610; SB265610.

IUPAC/Chemical Name

N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea

InChi Key

SEDUMQWZEOMXSO-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)

SMILES Code

O=C(NC1=C2N=NNC2=C(C#N)C=C1)NC3=CC=CC=C3Br

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 357.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Review. PubMed PMID: 26271598. 2: Masood A, Yi M, Belcastro R, Li J, Lopez L, Kantores C, Jankov RP, Tanswell AK. Neutrophil elastase-induced elastin degradation mediates macrophage influx and lung injury in 60% O2-exposed neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2015 Jul 1;309(1):L53-62. doi: 10.1152/ajplung.00298.2014. PubMed PMID: 26136527. 3: Goda AE, Erikson RL, Ahn JS, Kim BY. Induction of G1 Arrest by SB265610 Involves Cyclin D3 Down-regulation and Suppression of CDK2 (Thr160) Phosphorylation. Anticancer Res. 2015 Jun;35(6):3235-43. PubMed PMID: 26026083. 4: Keglowich L, Roth M, Philippova M, Resink T, Tjin G, Oliver B, Lardinois D, Dessus-Babus S, Gosens R, Hostettler Haack K, Tamm M, Borger P. Bronchial smooth muscle cells of asthmatics promote angiogenesis through elevated secretion of CXC-chemokines (ENA-78, GRO-α, and IL-8). PLoS One. 2013 Dec 5;8(12):e81494. doi: 10.1371/journal.pone.0081494. PubMed PMID: 24339939; PubMed Central PMCID: PMC3855263. 5: Clément S, Pascarella S, Conzelmann S, Gonelle-Gispert C, Guilloux K, Negro F. The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. J Hepatol. 2010 May;52(5):635-43. doi: 10.1016/j.jhep.2009.10.035. PubMed PMID: 20347177. 6: Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, Bradley ME. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol. 2010 Apr;159(7):1429-39. doi: 10.1111/j.1476-5381.2009.00623.x. PubMed PMID: 20233217; PubMed Central PMCID: PMC2850400. 7: Bradley ME, Bond ME, Manini J, Brown Z, Charlton SJ. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br J Pharmacol. 2009 Sep;158(1):328-38. doi: 10.1111/j.1476-5381.2009.00182.x. Erratum in: Br J Pharmacol. 2009 Oct;158(3):931. PubMed PMID: 19422399; PubMed Central PMCID: PMC2795238. 8: Milatovic S, Nanney LB, Yu Y, White JR, Richmond A. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 2003 May-Jun;11(3):213-9. PubMed PMID: 12753603; PubMed Central PMCID: PMC2667443. 9: Auten RL, Richardson RM, White JR, Mason SN, Vozzelli MA, Whorton MH. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther. 2001 Oct;299(1):90-5. PubMed PMID: 11561067.